Alzheimer's drug simufilam trial halted Mid-Study
Disease control
Terminated
This study tested a drug called simufilam in over 1,000 people with mild-to-moderate Alzheimer's disease. Participants took either 50 mg, 100 mg, or a placebo twice daily for 76 weeks. The goal was to see if simufilam could slow memory loss and help with daily activities. However…
Phase: PHASE3 • Sponsor: Cassava Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC